AlphAIAlphAI — Financial news for AI agents
biopharminternational.comSEP 302 min read$TEVA

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Teva Pharmaceutical Industries announced FDA approval of denosumab-adet (Degevma), a biosimilar to Amgen's Xgeva, for multiple indications including bone metastases and giant cell tumor. Approval was based on comparable efficacy and safety data. Teva anticipates U.S. launch in coming months, marking its second FDA-approved biosimilar in 2026.

Original reporting
biopharminternational.com
Published Sep 30, 2026, 4:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 6:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar — source image
Source · biopharminternational.com
Decision brief

The 30-second read

$TEVABullishHigh
01

Why it matters

The approval could drive incremental revenue and improve Teva's competitive position against Amgen.

02

Market read

Regulatory win for a major pharma player; likely short‑term stock uplift and longer‑term market share shift in biosimilars.

03

What to watch

Reimbursement rates, interchangeability status, and payer adoption could limit upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Teva announced FDA approval of Degevma, a denosumab biosimilar, expanding its oncology biosimilar portfolio.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

FDA approved Teva's Degevma biosimilar to Amgen's Xgeva, adding a new product to Teva's biosimilar portfolio.

Expected impact

upward pressure as investors price in future sales and market share gains.

Evidence & confidence

First‑report FDA approval of a high‑margin biologic biosimilar; market typically rewards such regulatory wins.

Market effects

Sector

Strengthens the oncology biosimilar segment and may pressure Amgen's Xgeva pricing.

Regional

U.S. biosimilar market sees added competition, potentially boosting overall adoption.

Global

Signals continued growth of global biosimilar pipelines, relevant for investors in biotech and pharma.

Counterpoint

What could challenge this read

If pricing pressure on Amgen outweighs Teva's market share gain, the stock may not rally.

Key entities

  • Company
    Teva Pharmaceutical Industries

    US‑listed pharmaceutical company receiving FDA approval for a new biosimilar.

  • Company
    Amgen

    Original developer of Xgeva, the reference product.

Read at source← All news

Also covered by

6 outlets

Related articles

SEP 30
$TEVAMedAI 8/10

Denosumab Biosimilar Approved For Existing Oncology Indications

The FDA approved Teva's Degevma (denosumab-adet) as a biosimilar to Xgeva (denosumab) for oncology-related bone disease indications. This is Teva's second biosimilar approval in 2026, following Ponlimsi (denosumab-adet) for osteoporosis. The approval covers prevention of skeletal-related events, treatment of giant cell tumor of bone, and hypercalcemia of malignancy.

targetedonc.com2 min
SEP 30
$TEVAMedAI 9/10

FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy

The FDA approved Teva Pharmaceuticals' denosumab-adet (Degevma) as a biosimilar to denosumab (Xgeva) for multiple indications, including skeletal-related events in cancer patients. This follows the March 2026 approval of denosumab-adet (Ponlimsi) as a biosimilar to denosumab (Prolia). Teva expects to launch both biosimilars in the U.S. soon, according to the company.

onclive.com2 min
SEP 29
$TEVAHighAI 9/10

FDA nod for Teva’s Degevma biosimilar

Teva Pharmaceutical Industries (TEVA) received FDA approval for Degevma, a biosimilar to Amgen's Xgeva (denosumab). Degevma is indicated for preventing bone complications in advanced cancer, treating giant cell tumors, and managing hypercalcemia of malignancy. This approval expands Teva's oncology portfolio.

thepharmaletter.com2 min
SEP 29
$TEVAHighAI 9/10

Teva Receives U.S. FDA Approval for Denosumab Biosimilar for Oncology Indications

Teva Pharmaceutical Industries received U.S. FDA approval for denosumab-adet, a biosimilar to denosumab, for all indications of the reference product. The approval expands Teva's biosimilar portfolio in oncology and bone health, offering a new treatment option. Denosumab-adet is approved for preventing skeletal-related events in advanced cancer, treating giant cell tumor of bone, and managing hypercalcemia of malignancy.

oncodaily.com2 min
SEP 29
$TEVAMedAI 8/10

Teva Pharma Secures FDA Nod For DEGEVMA, A Biosimilar To Xgeva

Teva Pharmaceutical (TEVA) received FDA approval for DEGEVMA, a biosimilar to Xgeva. The approval is based on data showing comparable efficacy, safety, and immunogenicity. DEGEVMA is indicated for bone complications in cancer patients and other conditions. Teva plans to launch DEGEVMA and PONLIMSI in the U.S. soon. TEVA stock closed at $38.88, up 0.31% in after-hours trading.

rttnews.com1 min